drug · protein
EB-613
Marketedupdated 3mo agoby $ENTXW Entera Bio Ltd.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Protein drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 8 investigational indications.
targets
Parathyroid hormone/parathyroid hormone-related peptide receptor
all catalysts(1)
Trials studying EB-613
- phase3A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism
- phase3A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
- —A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
- —A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
- —Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism
- phase3To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
- —Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women
- phase3Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures
News(1)
- STAT+: Pharmalittle: We’re reading about a battle between Lilly and Teva, psychedelic drugs, and moreA U.S. appeals court revived a Teva Pharmaceuticals lawsuit accusing Eli Lilly of breaching an agreement allowing Teva to market a generic version of Forteostat · 1mo ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that